Serial No.: 10/506592 Attorney Docket No.: ASZD-P01-659

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (1):



(1)

wherein[[:]]

$R^1$ is independently selected from $C_{1-6}$alkyl, $C_{5-7}$cycloalkyl, $C_{5-7}$cycloalkyl$C_{1-3}$alkyl, $C_{1-6}$alkoxy, $C_{5-7}$cycloalkoxy, $C_{5-7}$cycloalkyl$C_{1-3}$alkoxy, heterocyclyl, heterocyclyl$C_{1-3}$alkyl, heterocyclyloxy or heterocyclyl$C_{1-3}$alkoxy (wherein each of these groups is substituted on carbon ~~by~~ with 1, 2, or 3 hydroxy groups, provided that there is no more than one hydroxy group on the same carbon atom and a ring carbon atom adjacent to a ring heteroatom is not substituted by a hydroxy group), and groups of the formula A or A'[[:]]



(A)



(A')

wherein x is 0 or 1, r is 0, 1, 2, or 3, s is 1 or 2 and u is 1 or 2;

provided that in (A) the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

$R^2$ is phenyl or heteroaryl (each of which is optionally substituted ~~by~~ with 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, difluoromethyl, fluoromethyl, $C_{1-3}$alkoxy, $C_{1-3}$alkanoyl, carbamoyl, *N*-$C_{1-3}$alkylcarbamoyl, *N,N*-di-$C_{1-3}$alkylcarbamoyl,

sulfamoyl, *N*-$C_{1-3}$alkylsulfamoyl, *N,N*-di-$C_{1-3}$alkylsulfamoyl, and groups of the formulae B and B'[[:]]



(B)



(B')

wherein x is 0 or 1, r is 0, 1, 2, or 3, s is 1 or 2 and u is 1 or 2;

provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen);

m is 0, 1, or 2; and

$R^3$ is independently selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{2-4}$alkynyl, $C_{1-4}$alkoxy, $C_{1-4}$alkanoyl, fluoromethyl, difluoromethyl, trifluoromethyl, and trifluoromethoxy;

provided that when $R^1$ is of the formula A or A', then $R^2$ does not contain a group of the formula B or B', and when $R^2$ is of the formula B or B', then $R^1$ does not contain a group of the formula A or A';

or a pharmaceutically acceptable salt or prodrug thereof.

2. (currently amended) A compound of ~~the formula (1) as claimed in~~ claim 1, wherein:

$R^1$ is selected from $C_{1-6}$alkyl, $C_{5-7}$cycloalkyl, $C_{5-7}$cycloalkylmethyl, $C_{1-6}$alkoxy, $C_{5-7}$cycloalkoxy, $C_{5-7}$cycloalkyl$C_{1-3}$methoxy, heterocyclyl, heterocyclylmethyl, heterocyclyloxy and heterocyclylmethoxy (wherein each of these groups is substituted ~~by~~ with 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom), or $R^1$ is of the formula A or A';

$R^2$ is a phenyl or heteroaryl group (each of which is optionally substituted ~~by~~ with 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-$C_{1-3}$alkylcarbamoyl, N,N-di-$C_{1-3}$alkylcarbamoyl, sulfamoyl, N-$C_{1-3}$alkylsulfamoyl, N,N-di-$C_{1-3}$alkylsulfamoyl, a group of the formula B, and a group of the formula B');

or a pharmaceutically[[-]] acceptable salt or in-vivo hydrolysable ester thereof.

3. (currently amended) A compound of ~~the formula (1) as claimed in~~ claim 1, wherein:

$R^1$ is selected from $C_{1-6}$alkyl, $C_{5-7}$cycloalkyl, $C_{5-7}$cycloalkylmethyl, $C_{1-6}$alkoxy, $C_{5-7}$cycloalkoxy, and $C_{5-7}$cycloalkyl$C_{1-3}$methoxy, [[()]]wherein each group is substituted ~~by~~ with 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom[[)]];

$R^2$ is a phenyl or heteroaryl group (each of which is optionally substituted ~~by~~ with 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-$C_{1-3}$alkylcarbamoyl, N,N-di-$C_{1-3}$alkylcarbamoyl, sulfamoyl, N-$C_{1-3}$alkylsulfamoyl, and N,N-di-$C_{1-3}$alkylsulfamoyl);

or a pharmaceutically[[-]] acceptable salt or in-vivo hydrolysable ester thereof.

4. (currently amended) A compound of ~~the formula (1) as claimed in~~ claim 1, wherein:

$R^1$ is selected from ethyl, propyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, and cyclohexylmethyl, [[()]]wherein each group is substituted ~~by~~ with 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom[[)]];

$R^2$ is selected from phenyl, pyridyl, oxadiazolyl, oxazolyl, thiazolyl, and thienyl, [[()]]each of which ~~group~~ is optionally substituted ~~by~~ with 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-$C_{1-3}$alkylcarbamoyl, sulfamoyl, and N-$C_{1-3}$alkylsulfamoyl[[)]];

m is 1; and

$R^3$ is chloro;

or a pharmaceutically[[-]] acceptable salt or in-vivo hydrolysable ester thereof.

5. (currently amended) A compound of ~~the formula (1) as claimed in~~ claim 1, wherein:

$R^1$ is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3,4-dihydroxycyclopentyl, and 3,4-dihydroxycyclopentylmethyl;

$R^2$ is phenyl optionally substituted ~~by~~ with 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-$C_{1-3}$alkylcarbamoyl, sulfamoyl, and N-$C_{1-3}$alkylsulfamoyl;

m is 1 or 2; and

$R^3$ is hydrogen or halo;

or a pharmaceutically[[-]] acceptable salt or in-vivo hydrolysable ester thereof.

6. (currently amended) A process for preparing a compound of ~~formula (1), as defined in~~ claim 1 or a pharmaceutically[[-]] acceptable salt or an in-vivo hydrolysable ester thereof, which process comprises:

a) reacting an acid of the formula (2)[[:]]



(2)

or an activated derivative thereof; with an amine of formula (3)[[:]]

$HNR^1R^2$

(3); or

b) reacting an acid of the formula (4)[[:]]



(4)

or an activated derivative thereof; with an amine of formula (5)[[:]]

$H_2NCH_2CONR^1R^2$ [[:]]

(5)

~~wherein $R^1$, $R^2$, $R^4$, and $R^5$ are, unless otherwise specified, as defined in claim 1;~~

wherein any functional groups are optionally protected;

and thereafter if necessary[[:]]

i) converting a compound of the formula (1) into another compound of the formula (1);

ii) removing any protecting groups; or

iii) forming a pharmaceutically acceptable salt or in-vivo hydrolysable ester.

7. (currently amended) A pharmaceutical composition comprising a compound of ~~the formula (1) as claimed in any one of~~ claims 1~~, to 5~~ or a pharmaceutically[[-]] acceptable salt or in-vivo hydrolysable ester thereof and a pharmaceutically[[-]] acceptable diluent or carrier.

8-11. (canceled)

12. (currently amended) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia, or obesity in a warm-blooded animal~~, such as man,~~ in need of such treatment, ~~which comprises~~comprising administering to said animal an effective amount of a compound of ~~formula (1) as claimed in any one of~~ claims 1 ~~to 5~~.

13. (currently amendded) A method of treating type 2 diabetes in a warm-blooded animal~~, such as man,~~ in need of such treatment, ~~which comprises~~comprising administering to said animal an effective amount of a compound ~~of formula (1) as claimed in any one of~~ claims 1 ~~to 5~~.